Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF

Oncogene

Volumn 35, Issue 10, 2016, Pages 1328-1333

  Cisowski, J ^a   Sayin, V I ^a,b   Liu, M ^a   Karlsson, C ^a   Bergo, M O ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BETA GALACTOSIDASE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 4; K RAS PROTEIN; PROTEIN KINASE B; PROTEIN P15; PROTEIN P16; PROTEIN P19; UNCLASSIFIED DRUG; KRAS2 PROTEIN, MOUSE; PROTEIN P21;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; IN VITRO STUDY; LUNG TUMOR; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SENESCENCE; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; CARCINOGENESIS; CELL AGING; ENZYMOLOGY; FIBROBLAST; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY;

ANIMALS; CARCINOGENESIS; CELL AGING; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC LOCI; HUMANS; LUNG NEOPLASMS; MICE; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84960804625     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.186     Document Type: Article

References (26)

1. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761-774.
2. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008; 9: 517-531.
3. Maitra A, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Best. Pract Res Clin Gastroenterol 2006; 20: 211-226.
4. Goydos JS, Mann B, Kim HJ, Gabriel EM, Alsina J, Germino FJ et al. Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 2005; 200: 362-370.
5. Alsina J, Gorsk DH, Germino FJ, Shih W, Lu SE, Zhang ZG et al. Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma. Clin Cancer Res 2003; 9: 6419-6425.
6. Borras E, Jurado I, Hernan I, Gamundi MJ, Dias M, Marti I et al. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer 2011; 11: 406.
7. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011; 12: 175-180.
8. Kinno T, Tsuta K, Shiraishi K, Mizukami T, Suzuki M, Yoshida A et al. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations. Ann Oncol 2014; 25: 138-142.
9. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934.
10. Seth R, Crook S, Ibrahem S, Fadhil W, Jackson D, Ilyas M. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer. Gut 2009; 58: 1234-1241.
11. Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A et al. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 2006; 25: 3357-3364.
12. Yeang CH, McCormick F, Levine A. Combinatorial patterns of somatic gene mutations in cancer. FASEB J 2008; 22: 2605-2622.
13. Petti C, Molla A, Vegetti C, Ferrone S, Anichini A, Sensi M. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Res 2006; 66: 6503-6511.
14. Monticone M, Biollo E, Maffei M, Donadini A, Romeo F, Storlazzi CT et al. Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context. Mol Cancer 2008; 7: 92.
15. Karreth FA, DeNicola GM, Winter SP, Tuveson DA. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Mol Cell 2009; 36: 477-486.
16. Vandal G, Geiling B, Dankort D. Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation. PLoS One 2014; 9: e84745.
17. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243-3248.
18. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 2007; 21: 379-384.
19. DuPage M, Dooley AL, Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 2009; 4: 1064-1072.
20. Trejo CL, Juan J, Vicent S, Sweet-Cordero A, McMahon M. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E. Cancer Res 2012; 72: 3048-3059.
21. Andreadi C, Cheung LK, Giblett S, Patel B, Jin H, Mercer K et al. The intermediateactivity L597VBRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. Genes Dev 2012; 26: 1945-1958.
22. Matallanas D, Romano D, Al-Mulla F, O'Neill E, Al-Ali W, Crespo P et al. Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wildtype K-Ras. Mol Cell 2011; 44: 893-906.
23. Itahana K, Campisi J, Dimri GP. Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay. Methods Mol Biol 2007; 371: 21-31.
24. Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 2006; 7: 667-677.
25. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell 2006; 127: 265-275.
26. Sayin VI, Nilton A, Ibrahim MX, Agren P, Larsson E, Petit MM et al. Zfp148 deficiency causes lung maturation defects and lethality in newborn mice that are rescued by deletion of p53 or antioxidant treatment. PLoS ONE 2013; 8: e55720.